Analyzing Aspirin Use in Patients Without Cardiovascular Disease

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, JANUARY 22, 2019

Media advisory: To contact corresponding author Sean L. Zheng, B.M., B.Ch., M.A., M.R.C.P., email sean.zheng@nhs.net. The full study and editorial are linked to this news release.

Want to embed a link to this study in your story? This full-text link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/2721178?guestAccessKey=b6c6e6e2-80a8-449e-9278-a863ceaa9c67

 

Bottom Line: This study analyzed combined results from 13 randomized clinical trials with more than 164,000 participants to assess aspirin use with the prevention of cardiovascular events and bleeding in people without cardiovascular disease. Results suggest aspirin use was associated with lower risk (absolute risk reduction of 0.38 percent) for cardiovascular events (a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke) and increased risk of major bleeding (absolute risk increase of 0.47 percent). The role of aspirin for the primary prevention of cardiovascular events has remained controversial because of an increased risk for bleeding. This study (a meta-analysis that combines the results of multiple studies identified in a systematic review) is limited by the availability and quality of reported data.

Authors: Sean L. Zheng, B.M., B.Ch., M.A., M.R.C.P., Imperial College London, and Alistair J. Roddick, B.Sc., King’s College London, United Kingdom

(doi:10.1001/jama.2018.20578)

Editor’s Note:  Please see the article for additional information, including author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.